Islandia - Islandia - LYFJASTOFNUN (Icelandic Medicines Agency)

sandoz gmbh* - rifampicinum inn - hart hylki - 150 mg

Islandia - Islandia - LYFJASTOFNUN (Icelandic Medicines Agency)

sandoz a/s - tacrolimus monohydrate; tacrolimus - hart forðahylki - 0,5 mg

Islandia - Islandia - LYFJASTOFNUN (Icelandic Medicines Agency)

sandoz a/s - tacrolimus monohydrate; tacrolimus - hart forðahylki - 1 mg

Islandia - Islandia - LYFJASTOFNUN (Icelandic Medicines Agency)

sandoz a/s - tacrolimus; tacrolimus monohydrate - hart forðahylki - 2 mg

Islandia - Islandia - LYFJASTOFNUN (Icelandic Medicines Agency)

sandoz a/s - tacrolimus monohydrate; tacrolimus - hart forðahylki - 3 mg

Islandia - Islandia - LYFJASTOFNUN (Icelandic Medicines Agency)

alk-abelló a/s - phleum pratense; avena elatior; alopecurus pratensis; secale cereale; poa pratensis; dactylis glomerata; festuca pratensis; lolium perenne - húðstungupróf, lausn - 10 hep

Islandia - Islandia - LYFJASTOFNUN (Icelandic Medicines Agency)

novartis healthcare a/s - carbamazepinum inn - tafla - 200 mg

Islandia - Islandia - LYFJASTOFNUN (Icelandic Medicines Agency)

viatris aps - isoniazidum inn - tafla - 300 mg

Uni Eropa - Islandia - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - epcoritamab - lymphoma, large b-cell, diffuse - Æxlishemjandi lyf - tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) after two or more lines of systemic therapy.

Uni Eropa - Islandia - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - nivolumab, relatlimab - melanoma - antineoplastic agents, monoclonal antibodies - opdualag is indicated for the first line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell pd l1 expression < 1%.